Clinical operations note: globus-medical-layoffs-and-the-owner-question-a-procurement-perspective-on-chemistry-144

In late 2023, I was sitting in my office with a spreadsheet of spine implant vendors when a news alert popped up with two words I didn't want to see: Globus Medical layoffs. Globus Medical, one of the companies our surgical team had shortlisted because of the ExcelsiusGPS navigation system, had announced workforce reductions. I remember putting my coffee down and reading the headline twice.

I'm the procurement manager at a 220-bed community hospital. For twelve years, I've managed roughly $2.4 million a year in equipment, implants, and supplies, and I've tracked every order in a cost system that probably holds more of my memory than my own brain does. When a vendor announces layoffs, I don't assume it's the end of the world. But I also don't ignore it. If field service gets thinner, my operating room schedule feels it—in delays, cancellations, and friction.

If you've ever had to prepare a major capital recommendation in a hurry, you know the pressure. I had 48 hours to pull together a recommendation for a spine contract worth about $1.2 million over three years. Normally I would run a full RFP, but the timeline was what it was. I did the best I could with the information I had.

The 'Owner' Question

The first thing I did was search for 'globus medical owner.' I wanted to know who was behind the company and whether the layoffs meant deeper trouble. What I found was actually reassuring: Globus Medical is a public company, traded as GMED on the New York Stock Exchange. It doesn't have a single 'owner' in the traditional sense. The largest shareholders are institutional investors. And in 2023, the company completed its merger with NuVasive. Post-merger layoffs happen in almost every major integration—they're not pleasant, but they're also not proof that the company is falling apart.

Still, a layoff headline is a red flag. Not necessarily a deal-breaker, but a signal to ask harder questions. So I spent an afternoon reading investor materials and asking our existing vendor reps how their service teams were structured. That's when I realized I was making the same mistake I'd made years earlier with a chemistry analyzer: I was focusing on the product and the upfront price, not the total system that supports it.

The Chemistry Analyzer That Almost Cost Us $18,000

About two years before that, we were in the market for a new chemistry analyzer. It's easy to roll your eyes at lab equipment—until it goes down and every outpatient result gets delayed. We run a few thousand chemistry panels a month, which is not high volume. That nuance matters more than I want to admit.

One vendor quoted $62,000 upfront. The incumbent quoted $76,000. The cheaper option looked like a no-brainer on paper. Then I built a five-year TCO model. The cheaper analyzer used reagent packs designed for much higher throughput, so in our low-volume workflow, we would have thrown away roughly 12% of every pack. Add extra calibration frequency and a slightly less responsive service contract, and that $14,000 difference flipped into an $18,000 higher total cost over five years.

I almost missed it because I was counting the P.O. amount instead of the outcome. Trust me on this one: identical specifications do not mean identical costs.

Mammography and the Real Cost of Compliance

Mammography taught me the same lesson, but with an even stricter safety layer. When we bought a mammography system in 2022, the obvious comparison points were image quality and geometric footprint. The non-obvious category was compliance. Under the FDA's Mammography Quality Standards Act (MQSA), facilities have to meet requirements in 21 CFR 900—including annual physics surveys, phantom image testing, and documented quality control. As of January 2025, that's still the framework. Those requirements don't disappear because the purchase order is signed.

We chose a service contract that was slightly cheaper but didn't include the annual physics survey scheduling. Nine months later, we realized the survey window was about to lapse, and we had to pay a $3,400 emergency service fee to get a qualified medical physicist on site. That's the opposite of prevention over cure. A few extra minutes of checking the contract scope would have saved us from a very uncomfortable call with the radiologist.

What Is Wound Care, Really?

If I had asked that question five years ago, I would have said 'dressings and wound vacuums.' That's not wrong, but it's incomplete. What is wound care as a procurement category? It's a protocol: assessment, cleansing, debridement, infection management, moisture balance, and documentation. The products are only part of the system. The rest is consistency and prevention.

We standardized our wound care formulary and introduced a seven-point pressure injury prevention checklist. Over nine months, new facility-acquired pressure injuries dropped by almost 30%. I don't want to oversell it—part of that may have been a favorable patient mix. But the estimated treatment cost avoided was around $60,000, give or take. That's the 'check before you fix' mentality applied to patient care and procurement.

Back to Globus Medical

Once I had worked through those memories, the Globus Medical evaluation became clearer. I wasn't buying a chemistry analyzer or a mammography system from them, and I wasn't shopping for wound care products from them. But their broader portfolio—spine implants, surgical instruments, imaging systems, patient monitoring, energy devices, and the ExcelsiusGPS surgical navigation platform—mattered because we wanted a single partner who could support multiple OR needs. And their regulatory documentation was part of the deal. They included applicable FDA code references and reimbursement information in the technical packet. In a hospital, every missing code costs staff hours. That's not a theoretical cost; it's the difference between a clean handoff and a frustrating afternoon.

What changed my mind was not the technology. It was the ownership question. The 'owner' of Globus Medical in a stock-market sense is dispersed. The owner of the contract, from our perspective, is the person who makes sure service, training, and compliance all show up. That's what I needed to verify before signing.

The Checklist I Use Now

I've turned all this into a checklist. It applies to any medical device purchase—spine, lab, imaging, wound care supplies, all of it.

1. Get service response times in writing. If the rep changes or the company reorganizes, who answers the phone within four hours?
2. Build a five-year total cost model. Include consumables, calibration, training, downtime, and the labor cost of chasing documentation.
3. Verify regulatory requirements upfront. For mammography, ask about MQSA annual physics surveys and phantom testing. For a chemistry analyzer, ask about reagent waste and control frequency. For implants, ask for applicable FDA codes and reimbursement support.
4. Ask about the transition plan after a merger or layoff. A named contact matters more than a corporate promise.
5. Pilot before you scale. Try one service line first. Five minutes of verification beats five days of correction.

The Bottom Line

Even after we signed, I kept second-guessing. That's normal. Every procurement manager I know has hit 'confirm' and immediately wondered what they missed. The delivery arrived on time, the training went well, and eventually I let myself exhale.

Here's what I learned from the whole thing: don't let a headline make the decision for you, but don't ignore it either. Layoffs are a reason to dig deeper, not to run away. The same rule applies to any big medical purchase. Whether it's a chemistry analyzer, a mammography system, or a wound care protocol, the upfront cost is only the beginning. Prevention over cure is not just a clinical principle. It's a procurement principle too.